Go to content
UR Home

A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung)

URN to cite this document:
urn:nbn:de:bvb:355-epub-452644
DOI to cite this document:
10.5283/epub.45264
Heudobler, Daniel ; Schulz, Christian ; Fischer, Jürgen R. ; Staib, Peter ; Wehler, Thomas ; Südhoff, Thomas ; Schichtl, Thomas ; Wilke, Jochen ; Hahn, Joachim ; Lüke, Florian ; Vogelhuber, Martin ; Klobuch, Sebastian ; Pukrop, Tobias ; Herr, Wolfgang ; Held, Swantje ; Beckers, Kristine ; Bouche, Gauthier ; Reichle, Albrecht
[img]
Preview
License: Creative Commons Attribution 4.0
PDF - Published Version
(927kB)
Date of publication of this fulltext: 18 Mar 2021 18:53


Abstract

Background: Most non-small cell lung cancers occur in elderly and frequently comorbid patients. Therefore, it is necessary to evaluate the efficacy of biomodulatory active therapy regimen, concertedly interfering with tumor-associated homeostatic pathways to achieve tumor control paralleled by modest toxicity profiles. Patients and Methods: The ModuLung trial is a national, multicentre, ...

plus


Owner only: item control page
  1. Homepage UR

University Library

Publication Server

Contact:

Publishing: oa@ur.de

Dissertations: dissertationen@ur.de

Research data: daten@ur.de

Contact persons